{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=36&state=Alabama", "query": { "state": "Alabama", "city": "Birmingham", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1973, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=37&state=Alabama&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=35&state=Alabama&page_size=10" }, "source": "local", "last_synced_at": "2026-10-17T13:25:59.806Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03949855", "title": "Belimumab With Rituximab for Primary Membranous Nephropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Membranous Nephropathy", "Nephrotic Syndrome" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" }, { "name": "Placebo for Belimumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 58, "start_date": "2020-03-06", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-15T16:29:05.601Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03949855" }, { "nct_id": "NCT03435796", "title": "Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Gene-modified (GM) T cell therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1541, "start_date": "2018-07-19", "completion_date": "2043-05-29", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-01T09:55:08.113Z", "location_count": 103, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435796" }, { "nct_id": "NCT01524276", "title": "Product Surveillance Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Aortic, Peripheral Vascular and Venous Disorders", "Cardiac Rhythm Disorders", "Cardiovascular Disorders", "Coronary Artery Disease", "Diagnostic Techniques and Procedures", "Digestive Disorders", "Ear, Nose and Throat Disorder", "Intracranial Aneurysm", "Mechanical Circulatory Support", "Minimally Invasive Surgical Procedures", "Neurological Disorders", "Neurovascular", "Renal Insufficiency", "Respiratory Therapy", "Surgical Procedures, Operative", "Urological Disorders" ], "interventions": [], "intervention_types": [], "sponsor": "Medtronic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100000, "start_date": "2012-01", "completion_date": "2040-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-17T13:25:59.806Z", "location_count": 134, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 131 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524276" }, { "nct_id": "NCT07103746", "title": "Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Disorders" ], "interventions": [ { "name": "Placebo for Ublituximab", "type": "DRUG" }, { "name": "Ublituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-21", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-05T00:01:12.173Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07103746" }, { "nct_id": "NCT06907173", "title": "Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Status Epilepticus" ], "interventions": [ { "name": "Levetiracetam (LEV) (60 mg/Kg)", "type": "DRUG" }, { "name": "Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)", "type": "DRUG" }, { "name": "Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 770, "start_date": "2026-03-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T16:19:28.246Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907173" }, { "nct_id": "NCT06612268", "title": "A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Etavopivat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 510, "start_date": "2025-02-17", "completion_date": "2029-08-12", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T09:09:36.202Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06612268" }, { "nct_id": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib Fumarate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 1400, "start_date": "2020-07-21", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-13T22:01:26.325Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04293562" }, { "nct_id": "NCT07743463", "title": "A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Weight Management", "Obesity", "Overweight" ], "interventions": [ { "name": "ASC30 tablets A1", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascletis Pharma (China) Co., Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3003, "start_date": "2026-08-31", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T16:15:20.428Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743463" }, { "nct_id": "NCT07743450", "title": "A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Weight Management", "Obesity", "Overweight", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "ASC30 tablets A1", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascletis Pharma (China) Co., Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1560, "start_date": "2026-08-28", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T01:26:35.037Z", "location_count": 84, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743450" }, { "nct_id": "NCT07037459", "title": "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure With Mildly Reduced Ejection Fraction", "Heart Failure With Preserved Ejection Fraction", "Obesity" ], "interventions": [ { "name": "Maridebart cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5056, "start_date": "2025-06-25", "completion_date": "2030-09-29", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-07T00:43:33.512Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07037459" } ] }